Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology

被引:0
作者
Danjuma, Mohammed ibn-Mas'ud [1 ,2 ]
Mohamed, Mouhand F. H. [2 ]
ElShafei, Mohamad Nabil [2 ]
Fatima, Haajra [2 ]
Shokri, Shaikha Al [2 ]
Mohamed, Sara [2 ]
Abubeker, Ibrahim Yusuf [3 ]
Kartha, Anand [2 ]
Elzouki, Abdel-Naser [1 ,2 ]
Mohamedali, Mohamed Gaafar Hussein [2 ]
Mahgboub, Yahya [4 ]
Bidmos, Mubarak [1 ]
机构
[1] Qatar Univ, Coll Med, QU Hlth, Doha, Qatar
[2] Hamad Med Corp, Hamad Gen Hosp, Internal Med Dept, Doha, Qatar
[3] Rochester Reg Hlth Unity Internal Med Dept, Rochester, NY USA
[4] NHS Fdn Trust, Wirral Univ Hosp, Liverpool, Merseyside, England
关键词
cancer associated thrombosis; cancer thrombosis; DOAC; DVT; NOAC; novel oral anticoagulant; pulmonary embolism; WARFARIN;
D O I
10.1097/MD.0000000000019679
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients. Method: We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool. Results: We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT. Conclusion: Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.
引用
收藏
页数:4
相关论文
共 15 条
[1]   Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study [J].
Agnelli, Giancarlo ;
Becattini, Cecilia ;
Bauersachs, Rupert ;
Brenner, Benjamin ;
Campanini, Mauro ;
Cohen, Alexander ;
Connors, Jean Marie ;
Fontanella, Andrea ;
Gussoni, Gualberto ;
Huisman, Menno V. ;
Lambert, Catherine ;
Meyer, Guy ;
Munoz, Andres ;
de Sousa, Joaquim Abreu ;
Torbicki, Adam ;
Verso, Melina ;
Vescovo, Giorgio .
THROMBOSIS AND HAEMOSTASIS, 2018, 118 (09) :1668-1678
[2]   Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus [J].
Carrier, M. ;
Blais, N. ;
Crowther, M. ;
Kavan, P. ;
Le Gal, G. ;
Moodley, O. ;
Shivakumar, S. ;
Tagalakis, V ;
Wu, C. ;
Lee, A. Y. Y. .
CURRENT ONCOLOGY, 2018, 25 (05) :329-337
[3]   A generalized pairwise modelling framework for network meta-analysis [J].
Doi, Suhail A. R. ;
Barendregt, Jan J. .
INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE, 2018, 16 (04) :187-194
[4]  
Higgins J.P., 2011, BMJ, V343, pd5928, DOI [DOI 10.1136/BMJ.D5928, 10.1136/bmj.d5928]
[5]   Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial [J].
Lee, Agnes Y. Y. ;
Kamphuisen, Pieter W. ;
Meyer, Guy ;
Bauersachs, Rupert ;
Janas, Mette S. ;
Jarner, Mikala F. ;
Khorana, Alok A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (07) :677-686
[6]   Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis [J].
Li, Ang ;
Garcia, David A. ;
Lyman, Gary H. ;
Carrier, Marc .
THROMBOSIS RESEARCH, 2019, 173 :158-163
[7]  
Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
[8]   The Treatment of Venous Thromboembolism in Patients with Cancer [J].
Prandoni, Paolo .
THROMBOSIS AND EMBOLISM: FROM RESEARCH TO CLINICAL PRACTICE, VOL 1, 2017, 906 :123-135
[9]   Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism [J].
Raskob, Gary E. ;
van Es, Nick ;
Verhamme, Peter ;
Carrier, Marc ;
Di Nisio, Marcello ;
Garcia, David ;
Grosso, Michael A. ;
Kakkar, Ajay K. ;
Kovacs, Michael J. ;
Mercuri, Michele F. ;
Meyer, Guy ;
Segers, Annelise ;
Shi, Minggao ;
Wang, Tzu-Fei ;
Yeo, Erik ;
Zhang, George ;
Zwicker, Jeffrey I. ;
Weitz, Jeffrey I. ;
Buller, Harry R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (07) :615-624
[10]   Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis [J].
Ross, Jeremy A. ;
Miller, Marilyn M. ;
Hernandez, Cristhiam M. Rojas .
THROMBOSIS RESEARCH, 2017, 150 :86-89